

**WHO Prequalification Programme**  
**WHO PUBLIC ASSESSMENT REPORT (WHOPAR)**

**[HA480 trade name]<sup>1</sup>**

Ceftriaxone (sodium) 500 mg powder for solution for injection

**Abstract**

[HA480 trade name] manufactured at Egyptian International Pharmaceutical Industries Company, Egypt was included in the WHO list of prequalified medicinal products for the treatment of bacterial infections in Human Immunodeficiency Virus (HIV)/AIDS patients on 16 May 2014.

[HA480 trade name] is indicated for the treatment of bacterial infections. Detailed information on the use of this product is described in the Summary of Product Characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient of [HA480 trade name] is ceftriaxone.

The efficacy and safety profile of ceftriaxone is well established based on extensive clinical experience in the treatment of bacterial infections.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of ceftriaxone in bacterial infections, the team of assessors advised that [HA480 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [HA480 trade name] in the list of prequalified medicinal products.

**Summary of Prequalification Status for [HA480 trade name]:**

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

<b>Initial acceptance</b>	<b>Date</b>	<b>Outcome</b>
<b>Status on PQ list</b>	16 May 2014	listed
Pharmaceutical quality	07 April 2014	MR
Bioequivalence	28 April 2014	MR
Safety, efficacy	NA	NA
<b>GMP (re-)inspection</b>		
API	NA	NA

<sup>1</sup> Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

FPP	04 March 2013	MR
<b>GCP/GLP (re-)inspection</b>	NA	NA
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard] GMP: good manufacturing practice [quality standard] MR: meets requirements MR*: desk review (based on recent inspection reports) NA: not applicable, not available PQ: prequalification		

<b>Requalification</b>	17 February 2023
------------------------	------------------